OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Financial Times
6/2/2007

Oxford BioMedica rose 12 per cent to 51p, its highest level for more than six years, amid continued speculation that GlaxoSmithKline would be unveiled as its partner to develop the cancer vaccine Trovax.

Sunday Times Business
Major Share Movements
11-2-2007

Oxford Biomedica. + 7.5p. Hopes of GSK tie-up.

ProActive Investor
Feb. 2007

Clearly there are a few takeover rumours doing the rounds, and in the case of this company, the rumours appear to have some justification as this company does have some exciting products in the pipeline and controls a new gene delivery platform - OXB should be tempting to a bigger fish.

http://www.proactiveinvestors.co.uk/articles/article.asp?OXB2

- yes, but at what price?
I can't see a Takeover being the solution.....IF these drugs are as good as they appear...( that's an IF, until proven.) then who would sell at 50p-ish? Clearly the value is linked to the size of the "market-share" profits likely over several years...discounted as time-line moves further away; so maybe over five, or six years after aprovals, which should start "soon" - therefore I suspect 50p-ish is the starting point with the likes of Glaxo wanting to be certain they aren't spending money the don't need to. Sure it means they will "pay more" but large Pharmas don't want to take a scatter-gun approach and buy "anything that moves".....they have their own research facilities for "speculative" products...and presumably they only go with the best (of those).
So it's still a waiting game IMHO - we have to be patient.
Ludlow castle (a fine piece of masonry overlooking the Shropshire plains), will have to bide his time. As will those of us who have been focussed on this gem (er, -to be proved)---- just that bit longer.
The signs are good and in my opinion, the longer OXB can hold-off a partnering deal the better. ( They have sufficient funds I understand, standing at many Millions) - I suspect Prof AK isn't about to do a cheap deal....and as long as the OXB-products appear to be good, or even better than what's about currently, there is hope we could see ......1+
Ah! - that would be good, so patience - we have seen a sea-change from 30p-ish at the start of the year to about 50p-ish now (ie in two months). The market should still be buying March/April (end of PEP/ISA year), then we could see a further rise, maybe half as much again - say 60p-ish.....but expect a fall-back to 50p-ish over the long summer.....(I assume no approval, although this could be "anytime")...
Approval will make the Market react IMHO and a 50% rise is not impossible, so that would put OXB on a new plateau between 75-90p depending upon the results and the "then-sp".....will it hit 1 this year?....I have my doubts on approval-alone...........a deal would be nice.......since OXB needs a partner that knows the US-market.....but with Approval AND Partner-deal it would seem an easy reach.....so let's hope-so.

Well, holding-it looks fine from here.
....DYOR, as always.....

Thanks hongon, interesting read.

Fair value on a world-wide deal for TroVax, or a take-over, would be more like 140p to 160p.

Be nice to see it up @ that value of approx 1.00. per share

news out ?

PARKIN, I reckon OXB are currently worth 140p to 160p.

TroVax could secure the Company one of the biggest partnering deals in the biotech sector so far, for example, at least $100m upfront and $800m in milestones, maybe more judging by some other recent deals (they just keep getting bigger and bigger, and for ever more early stage drugs).

cynic whats your views on this one how do the chart much up their allso news out today with some more news out on march 6th..........

FWIW: there are to be institutional presentations next week (see RNS), and you can view the web-cast - not the best of software interpretations, but it's sure better than catching the train.

Threrfore I expect some price rise, as MM's get better prices once institutions show willingness to buy.
[Of course, the sp must be seen in relation to the Market as a whole - - if we see further falls (blamed on China?), then expect OXB to be affected however slightly.]

I'm just hoping OXB continues to gather strength; it looks a long way from the 20p region of not so long ago. Perhaps we shall have some progress on the trials - that would be bound to affect the sp as we get closer to pay-back time.

The Preliminary Annual Results and associated webcast presentation next Tuesday, should see Alan Kingsman giving a positive update on progress towards a deal for TroVax; and further positive press coverage of OXB.

Conclusion of a deal for TroVax must now be very close.

OXB's preliminary Annual Results today appear to say what shareholders wanted to hear regarding a deal for TroVax, i.e. it appears that potential partners have completed the due diligence mentioned late last year and are now just negotiating final terms. It also looks like it will be a global deal and thus large in financial terms. Details as follows:

CEO's Comment:

"...following extensive commercial discussions with potential partners for TroVax we are now negotiating final contractual terms and, subject to agreement on these terms and final approvals, we hope to conclude a licensing agreement in the near future."

Chairman's Report:

"Our key commercial focus in 2006 was to secure a commercial partner for TroVax. We have progressed to an advanced stage of negotiations with potential partners and remain committed to achieving this goal".

Oncology Overview:

"We expect further data from the TroVax clinical programme during 2007, including the first review by the Data Safety Monitoring Board of TRIST. Our commercial negotiations for TroVax are well advanced and, subject to final agreement, we expect to conclude a global licensing deal with a major pharmaceutical company".

TroVax:

"Oxford BioMedica remains committed to securing a suitable commercial partner for TroVax. The clinical data that have been generated to date place TroVax amongst the leading cancer immunotherapy candidates in development worldwide. The value of the programme continues to increase as more data emerge and with the start of Phase III development. Discussions with our lead prospective partners for a global licence to TroVax are at an advanced stage, and the Company expects these to reach a successful conclusion".

Oxford Mail
6th March 2007
Major Deal Looms for Cancer Treatment

Gene therapy company Oxford Biomedica confirmed yesterday that it was on the brink of signing a partnership deal for its cancer treatment TroVax.

If the deal goes ahead, Oxford Biomedica could become the first Oxford University spin-out company to see one of its cancer drugs launched by a major pharmaceutical firm.

The company, founded by Oxford dons Alan and Sue Kingsman, has developed a technique of introducing new genes into the body which encourage the immune system to fight back against cancer.
advertisement

Chief executive, Prof Alan Kingsman, said: "Following extensive commercial discussions with potential partners for TroVax, we are now negotiating final contractual terms and, subject to agreement on these terms and final approvals, we hope to conclude a licensing agreement in the near future."

More than 150 patients have now been treated with collectively more than 500 doses of TroVax in several clinical trials, producing an anti-tumour immune response in more than 95 per cent of patients.

Oxford BioMedica began recruiting patients in a Phase III trial in kidney cell carcinoma last November 2006, and trials in bowel and prostate cancer are ongoing.

If all goes well, TroVax could be registered in the United States in 2009. In the European Union, drug regulators have recommended TroVax should be treated as an "orphan drug" for kidney cancer, since no other treatment is available.

http://www.oxfordmail.net/business/news/display.var.1238298.0.major_deal_looms_for_cancer_treatment.php

Very encouraging - any views on the level of sp appreciation when a deal comes through?

queen, some are suggesting the share price may go to 150p to 200p on a deal for TroVax this year.

Investor's Chronicle
9th March 2007
Oxford Biomedica

Investors will be disappointed to hear that Oxford Biomedica's full-year results came and went without the announcement of a licensing deal for TroVax, its cancer product. TroVax is currently in Phase III trials that are being financed by the company. But chief executive, Professor Alan Kingsman insists that "discussions are maturing very nicely" and that the company is now very close to signing on the dotted line, which should give shareholders some comfort. However, he refused to give any timeline on a deal except to confirm that it should happen this year.

In the meantime, losses have nearly doubled as TroVax entered late-stage testing in patients with renal cancer, as well as other additional Phase III trials in colorectal and prostate cancer.

So Oxford Biomedica only has enough cash to fund the company until next year. Still, Professor Kingsman is confident that the hoped-for TroVax deal will come to fruition and that there will be no need for him to go cap-in-hand to the City again.

Meanwhile, ProSavin, the early-stage product for Parkinson's disease, is undergoing toxicology testing and gearing up to enter the clinic. This is likely to be in early 2008.

IC View:

The shares have more than doubled since July and could be volatile if a deal is slow to materialise. But for investors with an appetite for biotech, they are good value albeit higher risk.

LC - who is the "some" that have said they will go to 150 -200p? Whilst OXB has undoubted promise I've only seen that figure mentioned by one or two rampers on other BBs and they have since been banned for ramping and lying, surely you weren't referring to them?


Ludlow Castle - 09 Mar 2007 09:49 - 950 of 951
queen, some are suggesting the share price may go to 150p to 200p on a deal for TroVax this year.

I'd be surprised if they went that high - very pleasantly surprised!

OXB have today announced the purchase of a small independent biotech company, named Oxxon Therapeutics.

Oxxon's website states they have a viral based delivery platform (Hi-8 PrimeBoost); three immunotherapeutic drugs, covering cancer (melanoma) Hepatitis B (both of which have undertaken PII trials) and HIV; four preventative vaccines (3 in PII and one in PI); and intellectual property which includes 23 patent families resulting in over 100 issued patents and patent applications.

The cost to OXB is just 16m, which has been met by a small issue of 27m shares producing 5% dilution of the existing OXB stock. The purchase also gives OXB 3m cash from Oxxon's balance sheet.

The purchase appears to be a logical addition to OXB's portfolio and further spreads the risk. It also looks like very good value, i.e. just 16m for what amounts to a further delivery platform, seven new (largely mid stage) drugs, and associated IP. Infact, I can think of a couple of listed biotechs that have smaller pipelines but larger market capitalisations than 16m!

The announcement also contains a reference to the anticipated deal for TroVax.

-------------------------------

RNS Number:7430S
Oxford Biomedica PLC
12 March 2007

Oxford BioMedica to Acquire Oxxon Therapeutics

Acquisition Adds Melanoma Cancer Vaccine and Extends Immunotherapy Platform

Oxford BioMedica, ...announced today that it has entered into an agreement to acquire Oxxon Therapeutics Limited ('Oxxon'), a privately held biotechnology company, based in Oxford, UK. Oxxon is focused on the development of novel therapeutic vaccines for the treatment of cancer and infectious diseases.

Key aspects of the acquisition are:

1) Oxxon's lead cancer vaccine has completed a Phase II trial in melanoma, the only solid tumour that cannot be treated with Oxford BioMedica's TroVax.

2) Oxxon's technology has broad product applications in cancer and infectious diseases and will create new licensing opportunities.

3) Transaction value of 16 million will be satisfied by the issue of Oxford BioMedica shares.

4) Assets acquired include net cash of approximately 3 million.

The acquisition of Oxxon provides Oxford BioMedica with a complementary cancer immunotherapy product candidate. The product, Hi-8(R) MEL, has successfully completed a Phase II trial for the treatment of advanced melanoma. Oxxon has other therapeutic programmes addressing infectious diseases, including hepatitis B and HIV. In addition, Oxxon has a strong intellectual property estate that broadens and complements Oxford BioMedica's proprietary position in immunotherapy and gene-based medicines.

Professor Alan Kingsman, Chief Executive of Oxford BioMedica, commented, "We are very pleased to have been able to take this opportunity to acquire of Oxxon Therapeutics. The acquisition expands our immunotherapy pipeline and strengthens our intellectual property position in the field of immunology. Oxxon's Hi-8(R) MEL vaccine has generated encouraging Phase II results as a treatment of advanced melanoma. The market opportunity for an effective melanoma vaccine is substantial and this is a cancer type where our immunotherapy, TroVax, cannot be developed because, unlike the vast majority of human tumours, melanomas do not have 5T4 on the surface of the tumour cells. This acquisition is part of the implementation of a plan for the development of our pipeline following finalisation of a licensing deal for TroVax."

Iain Wilcock, Deputy Managing Director of Quester, a major investor in Oxxon, commented, "We are very pleased with this transaction, which combines the broad immunotherapy technology of Oxxon with one of the world's leading companies in cancer vaccines and gene therapy. There is clear synergy in this combination and, given Oxford BioMedica's technical and development expertise, we believe that the enlarged company can maximise the opportunity for Oxxon's technology."

Transaction details

The transaction is valued at 16 million, to be satisfied by the issue 27,551,628 Oxford BioMedica shares to Oxxon shareholders for the entire share capital of Oxxon and 4,219,618 shares for the repayment of a loan from Oxxon shareholders to Oxxon.

Oxxon's key investors, who as a result of the transaction will have an interest in Oxford BioMedica shares, are the venture capital firms Quester, MVM Life Science Partners and US-based East Hill Management.

Subject only to Admission the shares are expected to commence trading on 15 March 2007.